Saudi Arabia’s Biotechnology Future Begins at Home

A genetic test can identify a risk. It cannot decide a marriage. Saudi Arabia’s biotechnology ambitions would benefit from keeping that distinction in view.

In an article published this month in Arab Neews "Making science work for all", Princess Dr. Maha Al-Saud, CEO of the Future Investment Initiative, outlines an ambitious future. The National Biotechnology Strategy envisages domestic vaccine production, genomic medicine and advanced therapies, with biotechnology contributing more than $34bn to non-oil GDP by 2040.

Yet the example in her article that most interested me as a Saudi concerns a decision older than any of these technologies: whom to marry.

In 2004, the Kingdom introduced compulsory premarital screening for sickle-cell disease and thalassaemia. Couples identified as being at risk of passing on these disorders received genetic counselling but remained free to marry. Taking the test was mandatory. Acting on its implications was a private choice.A study of the programme's first six years documents that distinction.

It was a consequential one. By the time a couple seeks a marriage certificate, the wedding may already be a family undertaking. Affection, expectations and arrangements can give a proposed marriage considerable momentum. A result delivered in a clinic must compete with a future already imagined at home.

The state could require the test. It could not remove the social cost of acting on it.

The early results suggest that behaviour nevertheless changed. Between 2004 and 2009, the frequency of at-risk couples identified through screening fell by roughly 60%. Reported cancellation of marriage proposals among at-risk couples rose from 9.2% to 51.9%. Those figures describe screening outcomes and marriage decisions; they do not establish an equivalent reduction in affected births. But they show that genetic information was entering—and influencing—family deliberations.

Princess Maha uses the programme to illustrate science’s practical benefits. It also suggests something about how change takes hold. Scientific advice must become understandable and usable in circumstances that scientists do not control. A couple needs more than a result: time to consider it, confidence in the counselling and room to make a difficult decision.

That lesson extends to the more sophisticated medicine Saudi Arabia now hopes to develop. Princess Maha describes King Faisal Specialist Hospital’s production of CAR-T cells in Riyadh and reports a substantial reduction in the cost of this advanced cancer therapy. For a family confronting cancer, domestic production holds the promise of treatment closer to home. 

Realising that promise requires the ordinary machinery of healthcare to work well. Patients need timely diagnoses, appropriate referrals and access to treatment. A scientific achievement becomes a public benefit through these less celebrated steps.

The same discipline applies to research. Funding can buy equipment and buildings on a predictable timetable. Discovery is less accommodating. Experiments fail; promising approaches disappoint. Sustained progress requires institutions willing to support researchers through uncertainty and allow them to question established assumptions.

This makes Princess Maha’s observation that “strategies must be translated into treatments, companies and clinics” the central test of the ambition she describes.

The GDP target deserves attention. So do outcomes that are harder to fit into an investment presentation: a couple able to make an informed decision, a patient receiving specialist care without leaving the country, a Saudi researcher with the support to pursue an uncertain discovery.

Premarital screening brought science into one of the Kingdom’s most personal decisions. Its history suggests that biotechnology’s success depends as much on what happens after the laboratory result as on the result itself. The next chapter will be judged in clinics and homes, where national ambition becomes—or fails to become—a better life.

Share on: